www.moleculin.com/pancreatic-cancer/
"In June 2017, we announced the discovery of a metabolic inhibitor with what may be increased potential to treat pancreatic cancer. In pre-clinical testing, WP1234, a modification to WP1122, has shown improved in-vitro drug characteristics and a 20 to 50-fold greater ability to kill pancreatic cancer cell lines when compared with WP1122. We know that pancreatic cancer thrives even in a reduced oxygen environment and is highly dependent on glycolysis (energy production by cells required when sufficient oxygen is not available) to proliferate and survive. It’s important to qualify these findings by saying these results in animal models may not translate to humans. With this caveat in mind, we believe WP1234 may be a promising drug candidate to be studied for the treatment of pancreatic cancer.
Pancreatic cancer is still considered largely untreatable, so even modest gains in treating this disease could represent a significant clinical benefit. In pre-clinical testing, WP1234 improves on known inhibitors for glycolysis by increasing drug circulation time and providing other critical drug-like properties, which we believe should increase the potential for drug uptake by and destruction of tumor cells. We intend to pursue development opportunities with WP1234 for the treatment of pancreatic cancer and compare its activity with our other inhibitors, including WP1122."